Global Tuberculosis Report (2023) https://www.who.int/publications-detail-redirect/9789240083851 (Accessed on 6th November, 2023)

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. https://www.who.int/publications/i/item/9789240048126 (Accessed on 6th November, 2023)

Frieden T (2004) What is intermittent treatment and what is the scientific basis for intermittency? In: Frieden T (ed) Toman’s tuberculosis: case detection, treatment, and monitoring—questions and answers, 2nd edn. World Health Organization, Geneva, Switzerland, pp 130–138. Publication No. WHO/HTM/TB/2004.334

Feleke BE, Alene GD, Feleke TE, Motebaynore Y, Biadglegne F (2018) Clinical response of tuberculosis patients, a prospective cohort study. PLoS ONE 13(1):e0190207. https://doi.org/10.1371/journal.pone.0190207

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heysell SK, Moore JL, Keller SJ, Houpt ER (2010) Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16(10):1546–1553. https://doi.org/10.3201/eid1610.100374

Article  PubMed  PubMed Central  Google Scholar 

Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER (2013) Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat 2013:129723. https://doi.org/10.1155/2013/129723

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169–2183. https://doi.org/10.2165/00003495-200262150-00001

Article  CAS  PubMed  Google Scholar 

Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. https://iris.who.int/bitstream/handle/10665/260440/WHO-CDS-TB-2018.6-eng.pdf (Accessed on 6th November, 2023)

Märtson AG, Burch G, Ghimire S, Alffenaar JC, Peloquin CA (2021) Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol 17(1):23–39. https://doi.org/10.1080/17425255.2021.1836158

Article  CAS  PubMed  Google Scholar 

Falzon D, Jaramillo E, Gilpin C, Weyer K (2018) The role of novel approaches and new findings in the pharmacology of tuberculosis medicines in improving treatment outcomes. Clin Infect Dis 67:S365–S367. https://doi.org/10.1093/cid/ciy710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF et al (2018) Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis. Antimicrob Agents Chemother 62:e00636-e718. https://doi.org/10.1128/AAC.00636-18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E et al (2015) A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59:4181–4189. https://doi.org/10.1128/AAC.00115-15

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, Alffenaar JW (2015) The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 45(2):569–571. https://doi.org/10.1183/09031936.00142614

Article  PubMed  Google Scholar 

Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D (2015) Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 61(Suppl 1):S18-24. https://doi.org/10.1093/cid/civ426

Article  PubMed  Google Scholar 

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208(9):1464–1473. https://doi.org/10.1093/infdis/jit352

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez FJ, Nebert DW (1990) Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182–186. https://doi.org/10.1016/0168-9525(90)90174-5

Article  CAS  PubMed  Google Scholar 

Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I et al (1997) Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 127:289–293. https://doi.org/10.7326/0003-4819-127-4-199708150-00006

Article  CAS  PubMed  Google Scholar 

Peloquin CA, MacPhee AA, Berning SE (1993) Malabsorption of antimycobacterial medications. N Engl J Med 329(15):1122–1123. https://doi.org/10.1056/NEJM199310073291513

Article  CAS  PubMed  Google Scholar 

Berning SE, Huitt GA, Iseman MD, Peloquin CA (1992) Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 327:1817–1818. https://doi.org/10.1056/NEJM199212173272514

Article  CAS  PubMed  Google Scholar 

Gordon SM, Horsburgh CR Jr, Peloquin CA, Havlik JA Jr, Metchock B, Heifets L et al (1993) Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 168:1559–1562. https://doi.org/10.1093/infdis/168.6.1559

Article  CAS  PubMed  Google Scholar 

Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS et al (1996) Grand Rounds-Hammersmith Hospital. Persistent fever in pulmonary tuberculosis BMJ 313(7071):1543–1545

CAS  PubMed  Google Scholar 

Dieterlen P, Cassereau H, Lestradet H (1986) Malabsorption permanente de la rifampicine chez un diabétique atteint d’une maladie coeliaque [Permanent malabsorption of rifampicin in a diabetic with celiac disease]. Arch Fr Pediatr 43(6):421–422

CAS  PubMed  Google Scholar 

Polosa K, Murphy KJR, Krishnaswamy K (1984) Rifampicin kinetics in undernutrition. Br J Cin Pharmacol 17:481–484. https://doi.org/10.1111/j.1365-2125.1984.tb02377.x

Article  Google Scholar 

Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH et al (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43(7):848–854. https://doi.org/10.1086/507543

Article  CAS  PubMed  Google Scholar 

Gwilt PR, Nahhas RR, Tracewell WG (1991) The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmaco 20(6):477–490. https://doi.org/10.2165/00003088-199120060-00004

Article  CAS  Google Scholar 

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A et al (2005) Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40(10):1481–91. https://doi.org/10.1086/429321

Article  CAS  PubMed  Google Scholar 

Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D (2012) Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. J Int Assoc Physicians AIDS Care (Chic) 11(5):273–276. https://doi.org/10.1177/1545109712454454

Article  PubMed  Google Scholar 

Mtabho CM, Semvua HH, van den Boogaard J, Irongo CF, Boeree MJ, Colbers A et al (2019) Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 74(12):3537–3545. https://doi.org/10.1093/jac/dkz368

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW (2019) Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. Eur Respir J 54(3):1900373. https://doi.org/10.1183/13993003.00373-2019

Article  PubMed  Google Scholar 

Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL et al (2015) Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes 64(4):1459–1469. https://doi.org/10.2337/db14-0228

Article  CAS  PubMed  Google Scholar 

Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S (2017) Early interventions